Ken Griffin I Mab Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in I Mab stock. As of the latest transaction made, Citadel Advisors LLC holds 3,000 shares of IMAB stock, worth $3,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,000

Previous 11,900 74.79%

Holding current value

$3,720

Previous $22,000 77.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.58 - $1.9 $61,158 - $73,545	38,708 New	38,708 $64,000
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.9 $89,575 - $140,655	74,029 New	74,029 $140,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $323,974 - $422,814	-109,822 Reduced 99.56%	485 $1,000
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $247,404 - $593,609	-80,326 Reduced 42.14%	110,307 $381,000
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $1.41 Million - $2.12 Million	-437,074 Reduced 69.63%	190,633 $796,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $2.42 Million - $7.44 Million	602,966 Added 2437.11%	627,707 $2.52 Million
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $36,297 - $80,889	-4,389 Reduced 15.07%	24,741 $280,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $910,852 - $1.5 Million	-20,116 Reduced 40.85%	29,130 $1.38 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $2.29 Million - $3.38 Million	40,018 Added 433.66%	49,246 $3.57 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $195,460 - $342,851	4,084 Added 79.39%	9,228 $774,000
Q1 2021 May 17, 2021	SELL	$44.38 - $63.97 $3.19 Million - $4.6 Million	-71,847 Reduced 93.32%	5,144 $249,000
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $2.54 Million - $3.63 Million	76,991 New	76,991 $3.63 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

16.4M

Call Options Held

Put Options Held

1.9K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $103M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account